Efficacy and safety of Tregopil, a novel, ultra-rapid acting oral prandial insulin analog, as part of a basal-bolus regimen in type 2 diabetes: a randomized, active-controlled phase 2/3 study.
Insulin delivery
oral insulin
postprandial
rapid-acting insulin
type 2 diabetes mellitus
Journal
Expert opinion on pharmacotherapy
ISSN: 1744-7666
Titre abrégé: Expert Opin Pharmacother
Pays: England
ID NLM: 100897346
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
pubmed:
11
11
2022
medline:
22
11
2022
entrez:
10
11
2022
Statut:
ppublish
Résumé
Efficacy and safety of ultra-rapid acting oral prandial insulin Tregopil was compared with insulin aspart (IAsp) in patients with type 2 diabetes (T2D) on insulin glargine and metformin. In this open-label, active-controlled trial, patients with T2D, HbA The observed mean HbA Tregopil demonstrated an ultrafast, short-duration prandial profile with good safety. While Tregopil's early postprandial effects were comparable to IAsp, its late postprandial effects were inferior. The trial is registered at ClinicalTrials.gov (CT.gov identifier: NCT03430856).
Sections du résumé
BACKGROUND
UNASSIGNED
Efficacy and safety of ultra-rapid acting oral prandial insulin Tregopil was compared with insulin aspart (IAsp) in patients with type 2 diabetes (T2D) on insulin glargine and metformin.
RESEARCH DESIGN AND METHODS
UNASSIGNED
In this open-label, active-controlled trial, patients with T2D, HbA
RESULTS
UNASSIGNED
The observed mean HbA
CONCLUSIONS
UNASSIGNED
Tregopil demonstrated an ultrafast, short-duration prandial profile with good safety. While Tregopil's early postprandial effects were comparable to IAsp, its late postprandial effects were inferior.
TRIAL REGISTRATION
UNASSIGNED
The trial is registered at ClinicalTrials.gov (CT.gov identifier: NCT03430856).
Identifiants
pubmed: 36352762
doi: 10.1080/14656566.2022.2141569
doi:
Substances chimiques
Insulin
0
Insulin Aspart
D933668QVX
Insulin Glargine
2ZM8CX04RZ
Banques de données
ClinicalTrials.gov
['NCT03430856']
Types de publication
Randomized Controlled Trial
Clinical Trial, Phase II
Clinical Trial, Phase III
Journal Article
Langues
eng
Sous-ensembles de citation
IM